-+ 0.00%
-+ 0.00%
-+ 0.00%

NetraMark says MDPI AI journal study shows NetraAI improves clinical trial signal detection across three disease datasets

PUBT·09/10/2026 11:02:27
Listen to the news
NetraMark says MDPI AI journal study shows NetraAI improves clinical trial signal detection across three disease datasets
  • NetraMark reported publication of a peer-reviewed retrospective multi-dataset study in MDPI’s AI journal on Sept. 10, 2026.
  • Results were presented in the publication, not flagged for a future conference readout.
  • NetraAI-derived patient signatures improved performance for all tested models across schizophrenia, major depressive disorder, pancreatic cancer datasets.
  • Findings support a strategy to surface clinically relevant subgroups missed by standard analytics, informing trial enrichment and patient stratification decisions.
  • Pancreatic cancer work highlighted a compact genomic signature linked to treatment response, described as exploratory pending external validation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NetraMark Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100700PRIMZONEFULLFEED9824266) on September 10, 2026, and is solely responsible for the information contained therein.